ACR-70 response, rheumatoid arthritis 84
activator protein-1 (AP-1) pathway 240
acupuncture, value in fibromyalgia syndrome 31
acute quadriplegic myopathy 257–9
adalimumab
  use in psoriatic arthritis 182
  use in vasculitides 157
Adamantiades–Behçet’s disease see Behçet’s syndrome
ADAMTS-5 gene 41
adenine phosphoribosyltransferase deficiency 186
adenosine deaminase deficiency 186
adenylsuccinate lyase deficiency 186
ADFR (Activate, Decrease osteoclast activity, Free of treatment and Repeat) 230
adhesive capsulitis (frozen shoulder) 14–16, 212
adiponectin 43
Adson’s test 22
adynamic bone disease 248
alcohol consumption
  as cause of male osteoporosis 233
  effect on uric acid synthesis 185–6
  relationship to RA risk 98
alcoholic myopathy 257
alefacept, use in psoriatic arthritis 182
alemtuzumab 149
alendronate 223
  combination with cholecalciferol 220
  combination with raloxifene 230
  fracture prevention 224
  long-term use 224
  use during corticosteroid therapy 238, 240
  use in male osteoporosis 234
  use in Paget’s disease 243
alfacalcidol 219, 240, 250
alkaline phosphatase, levels in Paget’s disease 242
allantoin 184
allopurinol 106, 187, 188, 192–3, 194
alopecia, in SLE 122
alpha₂-adrenergic agonists, use in fibromyalgia syndrome 30
alpha₂-adrenergic antagonists, value in Raynaud’s phenomenon 137
alphavirus 208
Alu-Caps 250
Alzheimer’s disease, similarity to inclusion body myositis 262
American College of Rheumatology (ACR), classification criteria for SLE 117
aminocyl-tRNA synthetase antibodies 261, 262
Andersen syndrome 255
androgen deprivation therapy, osteoporosis risk 235
androgen therapy, male osteoporosis 234–5
angiogenesis, abnormalities in psoriasis 182
angiotensin II receptor antagonists, use in Raynaud’s phenomenon 137
angiotensin-converting enzyme (ACE) inhibitors
  use in Raynaud’s phenomenon 137
  use in scleroderma renal disease 142, 143
animal bites 201
ANKH gene 198
ankylosing spondylitis 4, 87
  BASMI 88–90
  diagnosis 173
  effects on heart 91
  mortality risk 91
anterior compartment syndrome 24
anterior cruciate ligament tears 6
antibiotic treatment
  of osteomyelitis 203
  of septic arthritis 201, 204
antibody treatments 149
  use in Behçet’s syndrome 166
  use in inflammatory myopathies 264
  use in psoriatic arthritis 181–2
  use in vasculitides 157, 158
  see also anti-TNF therapy
anti-CCP antibodies 5, 72, 73, 79–80
anti-centromere antibodies 110
anti-centromere antibodies see also anti-centromere antibodies
anti-convulsants, use in fibromyalgia syndrome 30
antidepressants, use in fibromyalgia syndrome 30
anti-dsDNA antibodies 110–11, 117
  in monitoring of SLE 124–5
anti-histone antibodies 117, 118
anti-hnRNP antibodies 112
anti-inflammator properties, statins 269
anti-IL-1 antibodies 112, 261, 262
anti-neutrophil cytoplasmic antibodies (ANCA) 155, 156–7, 157–8
anti-nuclear antibodies (ANAs) 78–9, 110, 113–15
anti-dsDNA 110–11
anti-hnRNP 112
anti-Jo-1 112, 261, 262
anti-Scl-70 112, 141, 142
anti-Sm and anti-RNP 111–12
anti-SSA/Ro and anti-SSB/La 111, 116, 129
in endometriosis 113
environmental factors 112
in scleroderma 141, 142
in Sjogren’s syndrome 130
in SLE 116–18
antioxidant intake, relationship to RA risk 97, 98
antiphospholipid antibodies 209
antiphospholipid syndrome (APS), risks during pregnancy 94
antiplatelet therapy
in giant cell arteritis 162
use in Raynaud’s phenomenon 137
anti-RA33 antibodies 112
anti-RNA polymerase III antibodies, scleroderma 142
anti-RNP antibodies 111–12
anti-Scl-70 antibodies 112, 141, 142
anti-Sm antibodies 111–12, 117
anti-SSA/Ro antibodies 111, 116, 129
anti-SSB/La antibodies 111, 129
antisyntetase syndrome 112
anti-TNF therapy 51, 80, 83, 85
in hepatitis C 207
in inflammatory myopathies 264
in psoriatic arthritis 182
safety monitoring 79
in vasculitides 157
see also etanercept; infliximab
anti-topoisomerase (anti-Scl-70) antibodies 112, 141, 142
antiviral antibodies 206
anxiety disorders, in fibromyalgia syndrome 28
aortic calcification 249–50
aortic insufficiency, AS 91
aplastic anaemia, parvovirus B19 as cause 207
apoB-100 immunization 158
APPROVe (Adenomatous Polyp Prevention on Vioxx) study 61
aromatase activity, relationship to bone loss 235
arthritis
acute monoarthritis, differential diagnosis 6–8
new onset
examination 3
history-taking 2–3
investigations 3–4
patterns of 4
in SLE 122
see also osteoarthritis; psoriatic arthritis; rheumatoid arthritis; septic arthritis; viral arthritis
arthritis mutilans 180
arthroscopic release, frozen shoulder 16
arthroscopy, in septic arthritis 201
aryalkanoic acids 61
2-arylpropionic acids (profens) 61
arzoxifene 230
ASC protein, role in gout 193
aspiration of joints 4
diagnosis of septic arthritis 7, 201
in gout 190
knee 8–9
in pseudogout 196
aspirin, low dose
concurrent non-selective NSAID therapy 61
use in Raynaud’s phenomenon 137
use in SLE 126
atherosclerosis, therapeutic strategies 158
athletes, risk of osteoarthritis 43
atrophic stage, scleroderma 141
autoantibodies, viral infection as trigger 206
azapropazone 193
azathioprine 148, 151
interaction with allopurinol 192
prediction of response 150
use in Behçet’s syndrome 166
use in GCA and PMR 161
use in inflammatory myopathies 262
use during pregnancy 95, 127
use in psoriatic arthritis 181
use in Sjogren’s syndrome 132
use in SLE 127
use in vasculitides 157
B19 (parvovirus) 206–7
back pain see low back pain
bacteraemia, risk factors 204
Barmah Forest Virus 208
basiliximab 149
bazedoxifene 230
Becker muscular dystrophy 255
Becker myotonia 255
Behçet’s syndrome 165–6
effect of pregnancy 94
genetic factors 166–7
insulin resistance 167
benzbromarone 193
betamethasone, intra-articular injection 51
bicipital tendinitis 13
biological agents
use in Behçet’s syndrome 166
use in inflammatory myopathies 264
use in psoriatic arthritis 181–2
use in vasculitides 157, 158
see also anti-TNF therapy
biomarkers of osteoarthritis 43
biopsy, in vasculitis 157
see also bone biopsy; muscle biopsy
bisphosphonates 218, 219–20, 223–4, 226, 231
in combination treatment 230
interaction with teriparatide 229
osteonecrosis risk 224
patient compliance 225
structure and function 222–3
use during corticosteroid therapy 238–9, 240
use in male osteoporosis 234
use in neuropathic arthropathy 213
use in osteoarthritis 51
use in Paget’s disease 242–3, 245
use in post-menopausal osteoporosis 225
blood cultures, septic arthritis 201
blood film appearance, rheumatoid arthritis 78
body mass index (BMI), relationship to osteoarthritis risk 45
bone biopsy 247, 248
bone histomorphometry 248
bone mineral density (BMD) 217–18
in diabetes 213
effect of strontium ranelate 228
effect of teriparatide 229
relationship to osteophyte formation 43
in renal osteodystrophy 248
bone mineralization, effect of bisphosphonates 223
bone remodelling, effects of statins 269
BONE study 224
bone turnover 247
bone turnover markers, Paget’s disease 242
bosentan 144
value in Raynaud’s phenomenon 138
botulinum toxin injection, fibromyalgia syndrome 31
breast cancer risk, effect of SERMs 228
breast-feeding, effect on rheumatoid arthritis risk 74
British Ankylosing Spondylitis Metrology Index (BASMI) 88–90
brucellosis 201
Burkholderia pseudomallei 201
butterfly rash 122
c-ANCA 156, 157
C-reactive protein (CRP) 4, 161
in giant cell arteritis 162
in rheumatoid arthritis 78, 80
in septic arthritis 9, 201
in SLE 125–6
caffeine intake, relationship to RA risk 98
Calcichew 250
calcineurin inhibitors 148–9
calcinosi s, in scleroderma 141
calcitonin
fracture prevention 224
use in neuropathic arthropathy 213
use in Paget’s disease 243
calcitriol (1,25-dihydroxy-vitamin D₃) 219, 247
calcium channel blockers, value in Raynaud’s phenomenon 137
calcium, in teriparatide therapy 229
calcium pyrophosphate dihydrate (CPPD) deposition disease (pseudogout) 8, 9, 195–6
associated conditions 196–7
diagnosis 196
hereditary 197
role of ANKH mutations 198
toll-like receptors 198
treatment 197–8
calcium supplementation 231
in corticosteroid therapy 238
men 234

cancers
association with dermatomyositis 260–1
breast cancer risk, effect of SERMs 228
as cause of lower back pain 172
vitamin D levels 219
capsaicin cream, value in osteoarthritis 47
carbon monoxide diffusion capacity, scleroderma 142
CARD15 gene 179
cardiac complications, ankylosing spondylitis 91
cardiovascular disease risk
effect of NSAIDs 61–4
effect of raloxifene 228
in hyperuricaemia 186–7
in psoriasis 182
in SLE 125–6
carnitine-palmitoyl transferase deficiency 257
carpal tunnel, anatomy 22
carpal tunnel release 24–5
endoscopic 26
carpal tunnel syndrome (CTS) 21
causes 23
clinical signs 23
imaging techniques 25–6
management 24–5
cartilage, in osteoarthritis 41
cartilage oligomeric matrix protein 43
caspase-1 role in gout 193
cauda equina syndrome 171
CCL2 162
CD4⁺ T lymphocytes 93
  in Sjögren’s syndrome 129
celecoxib, cardiovascular risk 61–2, 63
CENP antibodies 132
central core disease 253
central nervous system involvement
  Behçet’s syndrome 166
  SLE 127
centronuclear (myotubular) myopathy 254
cerivastatin 266
cervical rib syndrome 22
cervical rotation measurement 89, 90
cervical spinal cord stimulation, Raynaud’s phenomenon 137
channelopathies 255–6
Charcot joints (neuropathic arthropathy) 213
cheiroarthropathy 15, 212
Chikungunya 208
children, investigation of acute monoarthritis 9–10
chloroquine, value in psoriatic arthritis 181
cholecalciferol 219
  combination with alendronate 220
cholestyramine 268–9
chondrocalcinosis 195
  see also pseudogout
chondroitin, value in osteoarthritis 46, 49, 104
chronic kidney disease
  protein restriction 187–8
  use of allopurinol 192
chronic kidney disease-mineral and bone disorder (CKD-MBD) 246–7, 251
  adynamic bone disease 248
  diagnosis and management 248–50
  in early renal disease 250
  high turnover bone disease (osteitis fibrosa cystica) 247
  mixed 247
  osteomalacia 247
Churg–Strauss syndrome 155
  ANCA 157
  interferon therapy 158
cilostazol, value in Raynaud’s phenomenon 138
Cinacalcet 250
citrrullination 72
citrulline residues 5
CLASS (Celecoxib Long-term Arthritis Safety Study) 57
clofibrate, structure and function 222–3
clonidine, use in fibromyalgia syndrome 30
coenzyme Q₁₀ depletion 267
cognitive behavioural therapy, chronic low back pain 177
cognitive decline, effect of raloxifene 228
cognitive dysfunction, in SLE 127
colchicine 9, 106
  use in Behçet’s syndrome 166
  use in gout 190, 192–3
  use in osteoarthritis 51
  use in pseudogout 197
  use in vasculitides 157
collagen genes 41
combination therapy
  in osteoporosis 229–30
  in rheumatoid arthritis 84
  compartment syndromes 24
  complement deficiencies
    antinuclear antibodies 111
    association with SLE 120, 157
  compliance, bisphosphonate treatment 225
  computer use, dry eyes 130
  conduction disturbances, AS 91
  congenital heart block 94, 95, 111
  congenital myopathies 253–4
  connective tissue growth factor (CTGF), role in scleroderma 143
  continuous-focus osteomyelitis 203
  contractures, in scleroderma 141
  coracoacromial arch anomalies 13–14
  CORE (Continuing Outcomes Relevant to Evista) study 227
  Cori disease 256
  corticosteroid-induced osteoporosis, investigation and management 238–9
  corticosteroid therapy 147–8, 151
    as cause of male osteoporosis 233
    in carpal tunnel syndrome 24
    in frozen shoulder 16
    in GCA and PMR 161
    in gout 106
    in hepatitis C 207
    in inflammatory myopathies 262
    injection 9
      in carpal tunnel syndrome 24
      epidural 176–7
      in fibromyalgia syndrome 31
      in frozen shoulder 16
      intravenous, in giant cell arteritis 161, 162
      in osteoarthritis 51
      in pseudogout 197
      in psoriatic arthritis 181
      in rotator cuff disease 14
      in tennis elbow 19, 20
  long-term 162
  during pregnancy 95
  in rheumatoid arthritis 83, 84, 106
  in Sjögren’s syndrome 132
  in SLE 126, 127
  steroid myopathy 257, 258, 259
Index

in vasculitides 157
in viral arthritis 210
costoclavicular syndrome 22
COX isoenzymes, role in ulcer healing 57
COX-2 inhibitors 56, 57
cardiovascular risk 61–4
use in SLE 126
coxibs 61
  cardiovascular side effects 61–3
Coxsackie virus, as trigger for Sjögren’s syndrome 132
CPEO (Chronic Progressive External Ophthalmoplegia) 256
creatine kinase (CK) 262
  monitoring in statin therapy 266, 270
creatine supplementation, value during steroid therapy 259
CREST syndrome 110, 140
critical illness myopathy (CIM) 257–9
Crohn’s disease 179
CRTL1 gene 41
CRTM gene 41
cryoglobulinaemia 154
  antinuclear antibodies 111
crystal arthritis 7–8, 9
  see also gout; pseudogout
crystals, intra-articular 7
culture-negative septic arthritis 203
curcumin, effect on inflammation 100
cyclooxygenase (COX) inhibitors 56–7
  COX-2 selective drugs 56, 57
  cardiovascular risk 61–4
  use in SLE 126
cyclooxygenase (COX) isoenzymes, role in ulcer healing 57
cyclophosphamide 148, 151
  effect on fertility 94
  use in inflammatory myopathies 262
  use in scleroderma 143
  use in Sjögren’s syndrome 132
  use in SLE nephritis 127
  use in vasculitides 157
cyclosporin 149
  use in Behçet’s syndrome 166
  use in inflammatory myopathies 262
  use in psoriatic arthritis 181
  use in vasculitides 157
cytokine patterns in pregnancy 93
dacibuzumab 149
dactylitis, in psoriatic arthritis 180
dapsone, use in vasculitides 157
dehydroepiandrosterone (DHEA) levels in GCA and PMR 162–3
use in SLE 126–7
dental hygiene, Sjögren’s syndrome 131
depression
  in Sjögren’s syndrome 132
  in SLE 127
dermatomyositis (DM) 260–1
  antinuclear antibodies 111, 112, 113
  pathogenesis 264
dextropropoxyphene 51
diabetes
  bone complications 213
  cheiroarthropathy 15, 212
  joint disorders 213
  ligament, tendon and capsular problems 212
  musculoskeletal complications 211–12, 214–15
  osteoporosis risk 213–14
  type 2, risk from low vitamin D status 250–1
  vitamin D levels 219
diacerein 51
  value in osteoarthritis 104
diastolic dysfunction, AS 91
diclofenac
  cardiovascular risk 64
  side effects 57
diet 100–2
  in inflammatory myopathies 262
  recommendations in hyperuricaemia and gout 187
diabetes risk factors, rheumatoid arthritis 74, 97–8
dietary supplements 99–100
  see also vitamin D treatment
diffuse cutaneous scleroderma 140
diffuse idiopathic skeletal hyperostosis (DISH) 213
diffuse osteomyelitis 201
disc prolapse 171, 172
discectomy 176
discoid lupus 118
disease-modifying antirheumatic drugs (DMARDs) 83–4
  effect on fertility 93–4
  use during pregnancy 95
disease-modifying drugs, benefits in psoriatic arthritis 182
disease-modifying osteoarthritis drugs (DMOADs) 51–2, 104
dislocation, risk after hip replacement surgery 67
diuretics, use in carpal tunnel syndrome 24
DNA methylation abnormalities 119
docosahexaenoic acid 98
  benefit in RA 82–3
doxychycline, value in osteoarthritis 51, 53, 104
DRB1 gene 72
drug abuse, septic arthritis 201
Index

drug-induced lupus 118–19
drug interactions, with allopurinol 192
dry eyes, Sjögren’s syndrome 130
dry mouth, Sjögren’s syndrome 130–1
dual-energy X-ray absorptiometry (DEXA) 218
indications in men 233
Duchenne muscular dystrophy 255
duloxetine, use in fibromyalgia syndrome 30
Dupuytren’s disease (DD) 212
matrix metalloproteinases 213
eccentric loading exercises, rotator cuff disease 14
eculizumab, use in inflammatory myopathies 264
efalizumab 149
use in psoriatic arthritis 182
eicosapentaenoic acid 98
benefit in RA 82–3
elbow pain
golfer’s elbow 19
tennis elbow 18–19, 20
elderly people
polymyositis 103
gout 106
osteoarthritis 103–4
rheumatoid arthritis 104–6, 150
recurrent haemorrhagic shoulder 14
elemental diets 99
elimination diets 99
Emery–Dreifuss muscular dystrophy 255
endometriosis 113
endoscopic carpal tunnel surgery 26
endothelial dysfunction, scleroderma 143
endothelin (ET), role in scleroderma 143, 144
enthesitis, in psoriatic arthritis 180
entrapment neuropathies 21–4, 25–6
association with diabetes 211
carpal tunnel syndrome 24–5
as cause of heel pain 35
eosinophilia myalgia syndrome 112
epidermal growth factor (EGF), polymorphisms in psoriasis 182
epidural steroid injections, value in low back pain 176–7
epigenetic modifications, SLE 119, 120
Epstein–Barr virus (EBV), as trigger for rheumatoid arthritis 74–5
erythema infectiosum (‘slapped cheek’) 206
erythrocyte sedimentation rate (ESR) 4, 161
in giant cell arteritis 162
in polymyalgia rheumatica 160
in rheumatoid arthritis 78
in scleroderma 142
in septic arthritis 201
in SLE 125–6
etanercept 149
use in Behçet’s syndrome 166
use in inflammatory myopathies 264
use in psoriatic arthritis 182
use in vasculitides 157, 158
ethnic differences
in GCA and PMR 160
in gout 184
in psoriasis 179
in scleroderma 140
in SLE 123–4
in use of statins 267
etidronate 238–9
structure and function 222–3
use in Paget’s disease 243
etoricoxib, risk comparison with diclofenac 64
exercise
protection against fractures 218–19, 221
value in inflammatory myopathies 262
value in osteoarthritis 46
exercise programmes
in frozen shoulder 15–16
in joint replacement surgery 66
in plantar fasciitis 36
in rotator cuff disease 14
extractable nuclear antigens 110
ezetimibe 268, 269
facial pain, in fibromyalgia syndrome 28
facioscapulohumeral muscular dystrophy 255
family history, in new-onset joint pain 3
fasting, effect on inflammation 99
fatigue 91
in fibromyalgia syndrome 28
FDG-PET, in diagnosis of infections 204
febuxostat 188, 193
fenofibrate, use in gout 191, 193
fertility 93–4
in Sjögren’s syndrome 96
fetus, effects of maternal rheumatic disease 94–5
fever, significance in monoarthritis 7
fibrates, muscle side effects 266, 267, 268
fibrillin 140
fibroblast dysfunction, scleroderma 142, 143
fibroblast growth factors, polymorphisms in psoriasis 182
fibromyalgia syndrome (FMS) 27–8
epidemiology and aetiology 29
investigation 29, 30
outlook and management 29–31
fingernails, in psoriasis 3
fish oil, benefit in RA 82–3, 98–9
flavonoids 100
fluorinated steroids, risk of myopathy 257
fluoxetine, value in Raynaud’s phenomenon 137
fluvastatin, risk of muscle side effects 267, 268
α-fodrin antibodies 132
footwear choice, osteoarthritis 47
fracture prevention
raloxifene 227
strontium ranelate 228, 230
teriparatide 229
fractures, osteoporotic 218
in men 233–5
risk in glucocorticoid-induced osteoporosis 238
see also osteoporosis
frozen shoulder 13, 14–16, 17
fructose, effect on uric acid synthesis 185, 187
fruit intake, relationship to RA risk 97, 98

DHEA levels 162–3
epidemiology 162
gender differences 162
investigation 161, 163
treatment 161–2, 163
ginger extracts, value in osteoarthritis 52
glenohumoral osteoarthritis 12
glucocorticoid-induced osteoporosis 237–8, 240
investigation and management 238–9
glucocorticoid therapy see corticosteroid therapy
glucosamine, value in osteoarthritis 46, 48–9, 104
glycogen storage diseases 256–7
golfer’s elbow 19
gonococcal arthritis 7
Gottron’s sign 261
gout 7-8, 9, 10, 106, 189, 193–4
acute management 190
association with diabetes 211
dietary recommendations 187
gender and ethnic differences 184
investigations 190
molecular basis for inflammation 193
prophylaxis 190–3
risk factors 190
serum urate levels 7
see also hyperuricaemia; uric acid
graft-versus-host disease 112
similarity to scleroderma 144
Greek Atorvastatin and Coronary Heart Disease Evaluation study 186–7
green tea, value in osteoarthritis 52
headaches
in fibromyalgia syndrome 28
in SLE 127
health status, in psoriatic arthritis 182
heart, effects of ankylosing spondylitis 91
Heberden’s nodes, genetic predisposition 41
heel pain
common causes 34
plantar fasciitis 33–7
heel spurs 34
Helicobacter pylori infection, interaction with NSAID therapy 57, 59
Henoch–Schönlein purpura 154
Hep2000 cell line 110
hepatitis, viral arthritis 206
hepatitis B 208
hepatitis C 207–8, 209
cryoglobulinaemia 154
hereditary neuropathy with liability to the pressure palsies (HNPP) 2
<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>hexosamine biosynthetic pathway</td>
<td>48-9</td>
</tr>
<tr>
<td>high turnover bone disease (osteitis fibrosa cystica)</td>
<td>247</td>
</tr>
<tr>
<td>hip, septic arthritis</td>
<td>9</td>
</tr>
<tr>
<td>hip fracture, morbidity</td>
<td>233</td>
</tr>
<tr>
<td>hip fracture prevention, strontium ranelate</td>
<td>228</td>
</tr>
<tr>
<td>hip replacement surgery</td>
<td>65, 69</td>
</tr>
<tr>
<td>complications</td>
<td>67</td>
</tr>
<tr>
<td>exercise programmes</td>
<td>66</td>
</tr>
<tr>
<td>indications</td>
<td>66, 67</td>
</tr>
<tr>
<td>minimal incision</td>
<td>68</td>
</tr>
<tr>
<td>prosthesis survival</td>
<td>67-8</td>
</tr>
<tr>
<td>value of weight reduction</td>
<td>65-6</td>
</tr>
<tr>
<td>histamine H₂ receptor antagonists, use with NSAIDs</td>
<td>56</td>
</tr>
<tr>
<td>histone modification</td>
<td>119</td>
</tr>
<tr>
<td>HIV infection</td>
<td>208</td>
</tr>
<tr>
<td>association with inclusion body myositis</td>
<td>262</td>
</tr>
<tr>
<td>HLA-B51</td>
<td>166</td>
</tr>
<tr>
<td>HLA-Cw0602 allele</td>
<td>179</td>
</tr>
<tr>
<td>HLA-DRB1*04</td>
<td>160, 162</td>
</tr>
<tr>
<td>homocysteine levels, Behcet’s syndrome</td>
<td>167</td>
</tr>
<tr>
<td>homogeneous staining, ANA</td>
<td>110, 117</td>
</tr>
<tr>
<td>hormone replacement therapy (HRT)</td>
<td>218, 231</td>
</tr>
<tr>
<td>combination with teriparatide</td>
<td>230</td>
</tr>
<tr>
<td>in osteoarthritis</td>
<td>43, 51</td>
</tr>
<tr>
<td>use in SLE</td>
<td>119</td>
</tr>
<tr>
<td>HTLV (human T-lymphotropic virus)-1</td>
<td></td>
</tr>
<tr>
<td>infection, association with inclusion body myositis</td>
<td>262</td>
</tr>
<tr>
<td>human bites</td>
<td>201</td>
</tr>
<tr>
<td>hyaluronan, serum levels</td>
<td>43</td>
</tr>
<tr>
<td>hyaluronic acid, intra-articular injection</td>
<td>47, 49, 104</td>
</tr>
<tr>
<td>hydralazine, association with DIL</td>
<td>118</td>
</tr>
<tr>
<td>hydroxychloroquine</td>
<td>149</td>
</tr>
<tr>
<td>use in hepatitis C</td>
<td>207</td>
</tr>
<tr>
<td>use in psoriatic arthritis</td>
<td>181</td>
</tr>
<tr>
<td>use in Sjögren’s syndrome</td>
<td>132</td>
</tr>
<tr>
<td>use in SLE</td>
<td>126</td>
</tr>
<tr>
<td>hyperbaric oxygen therapy, osteomyelitis</td>
<td>203</td>
</tr>
<tr>
<td>hypergammaglobulinaemia, antinuclear antibodies</td>
<td>111</td>
</tr>
<tr>
<td>hyperglycaemia, association with osteoarthritis</td>
<td>41-2</td>
</tr>
<tr>
<td>hyperkalaemic periodic paralysis</td>
<td>255</td>
</tr>
<tr>
<td>hyperostosis</td>
<td>213</td>
</tr>
<tr>
<td>hyperparathyroidism, vascular dysfunction</td>
<td>250</td>
</tr>
<tr>
<td>hypertensive disorders of pregnancy</td>
<td>96</td>
</tr>
<tr>
<td>hyperuricaemia</td>
<td>188</td>
</tr>
<tr>
<td>cardiovascular disease risk</td>
<td>186-7</td>
</tr>
<tr>
<td>causes</td>
<td>185-6</td>
</tr>
<tr>
<td>dietary recommendations</td>
<td>187</td>
</tr>
<tr>
<td>treatment</td>
<td>187</td>
</tr>
<tr>
<td>see also gout</td>
<td></td>
</tr>
<tr>
<td>hypogonadism</td>
<td>233</td>
</tr>
<tr>
<td>testosterone treatment</td>
<td>234-5</td>
</tr>
<tr>
<td>hypokalaemic periodic paralysis</td>
<td>255</td>
</tr>
<tr>
<td>hypomethylation, association with SLE</td>
<td>119</td>
</tr>
<tr>
<td>hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>chondrocalcinosis</td>
<td>197</td>
</tr>
<tr>
<td>gout</td>
<td>190</td>
</tr>
<tr>
<td>hypoxanthine phosphoribosyltransferase (HPRT)</td>
<td></td>
</tr>
<tr>
<td>deficiency</td>
<td>186</td>
</tr>
<tr>
<td>ibandronate</td>
<td>223, 224</td>
</tr>
<tr>
<td>use in male osteoporosis</td>
<td>234</td>
</tr>
<tr>
<td>use in Paget’s disease</td>
<td>243</td>
</tr>
<tr>
<td>ibuprofen</td>
<td></td>
</tr>
<tr>
<td>cardiovascular risk</td>
<td>63</td>
</tr>
<tr>
<td>interaction with aspirin</td>
<td>61</td>
</tr>
<tr>
<td>imaging</td>
<td></td>
</tr>
<tr>
<td>chronic low back pain</td>
<td>176</td>
</tr>
<tr>
<td>rheumatoid arthritis</td>
<td>78</td>
</tr>
<tr>
<td>see also magnetic resonance imaging; positron emission tomography (PET);</td>
<td></td>
</tr>
<tr>
<td>radiography</td>
<td></td>
</tr>
<tr>
<td>immobility, muscle loss</td>
<td>259</td>
</tr>
<tr>
<td>immunoglobulin, use in inflammatory myopathies</td>
<td>262</td>
</tr>
<tr>
<td>immunosuppressive drugs</td>
<td>147</td>
</tr>
<tr>
<td>antibody treatments</td>
<td>149</td>
</tr>
<tr>
<td>antiproliferative and antimitabolic drugs</td>
<td>148</td>
</tr>
<tr>
<td>see also azathioprine; cyclophosphamide; leflunomide; methotrexate; mycophenolate mofetil</td>
<td></td>
</tr>
<tr>
<td>calcineurin inhibitors</td>
<td>148-9</td>
</tr>
<tr>
<td>glucocorticoids</td>
<td>147-8</td>
</tr>
<tr>
<td>see also corticosteroid therapy</td>
<td></td>
</tr>
<tr>
<td>hydroxychloroquine</td>
<td>149</td>
</tr>
<tr>
<td>indications for use</td>
<td>150</td>
</tr>
<tr>
<td>sulphasalazine</td>
<td>149</td>
</tr>
<tr>
<td>therapeutic monitoring</td>
<td>149-50, 151</td>
</tr>
<tr>
<td>use in vasculitides</td>
<td>157</td>
</tr>
<tr>
<td>impingement theory, rotator cuff disease</td>
<td>13-14</td>
</tr>
<tr>
<td>incision length, hip replacement</td>
<td>68</td>
</tr>
<tr>
<td>inclusion body myositis (IBM)</td>
<td>261-2</td>
</tr>
<tr>
<td>pathogenesis</td>
<td>264</td>
</tr>
<tr>
<td>indurative stage, scleroderma</td>
<td>141</td>
</tr>
<tr>
<td>infection, risk after joint replacement surgery</td>
<td>67</td>
</tr>
<tr>
<td>infections</td>
<td></td>
</tr>
<tr>
<td>association with arthritis</td>
<td>3</td>
</tr>
<tr>
<td>as cause of lower back pain</td>
<td>172</td>
</tr>
<tr>
<td>as cause of Paget’s disease</td>
<td>242</td>
</tr>
<tr>
<td>as trigger for giant cell arteritis</td>
<td>154, 160</td>
</tr>
<tr>
<td>as trigger for rheumatoid arthritis</td>
<td>74-5</td>
</tr>
<tr>
<td>as trigger for Sjögren’s syndrome</td>
<td>132</td>
</tr>
<tr>
<td>see also septic arthritis</td>
<td></td>
</tr>
<tr>
<td>inflammation assessment, SLE</td>
<td>125-6</td>
</tr>
</tbody>
</table>
inflammatory lower back pain 172, 173
inflammatory markers, as outcome measures 88
inflammatory myopathies 260–2
  diagnosis and management 262–3
  use of biological agents 264
infliximab 149
  use in Behçet’s syndrome 166
  use in GCA and PMR 161
  use in inflammatory myopathies 264
  use in psoriatic arthritis 182
  use in vasculitides 157, 158
insulin resistance
  in Behçet’s syndrome 167
  possible effect of glucosamine supplementation 49
interferon therapy
  in Behçet’s syndrome 166
  in Churg–Strauss syndrome 158
  interferon 1, possible role in SLE 119–20
  topical use in Sjögren’s syndrome 131
interleukin-1 inhibitors 83
interleukin-18
  association with Behçet’s syndrome 167
  levels in DM and PM 164
intermalleolar distance measurement 89, 90
interstitial pulmonary fibrosis 112
intervertebral disc prolapse 171, 172
discectomy 176
intravenous drug users, septic arthritis 201
intravenous immunoglobulin, use in vasculitides 157
irritable bowel syndrome, in fibromyalgia syndrome 28
joint aspiration 4
  diagnosis of septic arthritis 7, 201
  in gout 190
  knee 8–9
  in pseudogout 196
joint count 88, 89
  prognostic value in RA 80
joint pain
  acute monoarthritis, differential diagnosis 6–8
  new onset
    examination 3
    history-taking 2–3
    investigations 3–4
joint replacement surgery 65, 69
  complications 67
  exercise programmes 66
  indications 66, 67
  minimal incision 68
  perioperative methotrexate therapy 66–7
  prosthesis survival 67–8
  uniconompartmental knee arthroplasty 68
  value of weight reduction 65–6
juvenile Paget’s disease 243
Kawasaki syndrome 155
Kearns–Sayre syndrome 256
Kelley–Seegmiller syndrome 186
knee joint
  aspiration 8–9
  magnetic resonance imaging 10
  monoarthritis, differential diagnosis 6–8
  osteoarthritis, corticosteroid injection 51
knee replacement surgery 65, 69
  complications 67
  indications 66, 67
  post-operative weight gain 66
  prosthesis survival 68
  uniconompartmental 68
laminin-1 113
lansoprazole, gastric protection in NSAID therapy 59
large vessel vasculitis 155
laser therapy, Raynaud’s phenomenon 137
lasofoxifene 230
late-onset RA (LORA) 105–6, 150
lateral cutaneous nerve of the thigh, meralgia paraesthetic 24
lateral epicondylitis (tennis elbow) 18–19
  RCT of treatments 20
leflunomide 148
  avoidance during pregnancy 95
  safety monitoring 79
  use in psoriatic arthritis 181
  use in Sjögren’s syndrome 132
leptin levels, Behçet’s syndrome 167
Lesch–Nyhan syndrome 186
LIFE (Losartan Intervention for Endpoint Reduction) study 187
lifestyle modification, SLE 126
ligamentum flavum hypertrophy 171
limb girdle muscular dystrophy 255
limited cutaneous scleroderma 140
limited joint mobility (LJM), diabetes 212
linoleic acid 46
α-linolenic acid 46
local anaesthetic injection, fibromyalgia syndrome 31
losartan, use in gout 191, 193
low back pain
  acute 169–70, 174
  ankylosing spondylitis 173
  causes 170–1
low back pain – contd
  acute – contd
    management 172–3
    outcome 173
    specific pathology 171–2
  chronic
    clinical examination 175–6
    imaging 176
    opioid use 177
    treatment 176–7
  indicators for nerve root problems 171
  inflammatory 172, 173
  ‘red flags’ 170
  risk factors 170
Low-Dye taping, plantar fasciitis 35
lumbar flexion measurement 89, 90
LUMINA (lupus in minorities: nature versus nurture) study 124, 126
lupus nephritis 122, 124, 127, 150
Lyme disease 7
lymphoma, risk in Sjögren’s syndrome 132
M1-2 antibodies 262
McArdle disease 257
magnetic resonance imaging (MRI)
  in carpal tunnel syndrome 24–5
  in giant cell arteritis 161
  in inflammatory myopathies 262
  of knee joint 10
  in low back pain 176
  in osteomyelitis 203
  in psoriatic arthritis 180
male osteoporosis 233–5
  diagnosis and management 236
malignancy
  association with dermatomyositis 260–1
  breast cancer risk, effect of SERMS 228
  as cause of lower back pain 172
  vitamin D levels 219
malignant bone pain 2
malignant hyperthermia 255–6
mammalian target of rapamycin (mTOR) 148
manipulation under anaesthesia (MUA), value in
  frozen shoulder 16
matrix metalloproteinases (MMPs)
  in Dupuytren’s disease 213
  as therapeutic targets 51
  medial calcaneal nerve entrapment 35
  medial compartment syndrome 24
  medial epicondylitis (golfer’s elbow) 19
  median neuritis 23
  Mediterraneand diet 98
  medium vessel vasculitis 154–5
medullary osteomyelitis 201
MELAS (Myopathy, Encephalopathy, Lactic Acidosis and Stroke) 256
meliodosis 201
meloxicam, cardiovascular risk 62
membranous staining, ANA 110
menopause
  effect on BMD 218
  effect on osteoarthritis risk 43
meralgia paraesthetica 24
mercaptopurine, interaction with allopurinol 192
MERRF (Myoclonic Epilepsy with Ragged Red Fibres) 256
metabolic syndrome, association with
  hyperuricaemia 186
methotrexate therapy 148, 151
  effect on fertility 94
  in GCA and PMR 161
  in inflammatory myopathies 262
  joint replacement surgery 66–7
  prediction of response 150
  in psoriasis 181
  teratogenicity 95
  in rheumatoid arthritis 84, 86
  safety monitoring 79
  in scleroderma 143
  in Sjögren’s syndrome 132
  in vasculitides 157
methylene tetrahydrofolate reductase levels 150
methylprednisolone
  epidural injection 177
  intra-articular injection 51
  intravenous, in inflammatory myopathies 262
  use in GCA 161, 162
microchimaerism hypothesis, scleroderma 144
microscopic polyangiitis 155
ANCA 157
minimal incision, hip replacement surgery 68
minocycline 51
  association with DIL 118
misoprostol 56
mitochondrial myopathies 256
mitochondrial toxicity, statins 269
mixed connective tissue disease (MCTD),
  antinuclear antibodies 111, 112, 113
MMP-3 gene 41
MOBILE study 224
monitoring
  of immunosuppressive treatment 149–50, 151
  of systemic lupus erythematosus (SLE) 123–5
monoarthritis 4
  diagnostic errors 7
  differential diagnosis 6–8
  see also gout; septic arthritis
monocarboxylate transporter 4 inhibition, statins 269
monoclonal antibodies 149
monocyte chemoattractant protein-1 (MCP-1) 162
MORE (Multiple Outcome of Raloxifene Evaluation) trial 227, 228
morpha 140
see also scleroderma
movement disorders, in fibromyalgia syndrome 28
multidisciplinary management, low back pain 177
multiple sclerosis, vitamin D levels 219
multiplex technologies 113
muscle biopsy 262
muscle complications of statins 211-12, 266-7, 269-70
diagnosis and management 267-9
pathogenesis 269
rhabdomyolysis 267
muscular dystrophies 254-5
muscular infarction, diabetic 212
muscular pains, Sjögren’s syndrome 131
myalgia 266
mycophenolate mofetil (MMF) 148, 150
use in psoriatic arthritis 181
use in scleroderma 143
use in SLE nephritis 127
use in vasculitides 157
*Mycoplasma pneumoniae*, as trigger for giant cell arteritis 154, 160
myoadenylate deaminase deficiency 186
myocardial infarction risk
after joint replacement surgery 67
NSAIDs 57, 61-4
myopathies
acquired
alcoholic myopathy 257
critical illness myopathy 257-9
steroid myopathy 258, 259
channelopathies 255-6
classification 254
congenital 253-4
in congenital metabolic disorders 256-7
inflammatory 260-2
diagnosis and management 262-4
mitochondrial 256
muscular dystrophies 254-5
myositis-specific antibodies (MSA) 262
myotonia 255
myotonic dystrophy 254-5
myotubular (centronuclear) myopathy 254

n-3 fatty acid supplementation, value in osteoarthritis 46-7
N-arylanthraniolic acids 61
nailfold capillaries, Raynaud’s phenomenon 135, 140, 141
NALP proteins, role in gout 193
naproxen, interaction with aspirin 61
*NAT9* gene 179
nemaline rod myopathy 253-4
neonatal lupus syndrome 94-5
Neoral see cyclosporin
nerve root problems 171
neural theory of tendinopathy 16
neuropathic arthropathy (Charcot joints) 213
neuropathies, Sjögren’s syndrome 131-2
niacin, muscle symptoms 268
nifedipine, value in Raynaud’s phenomenon 137
night pain, shoulder 11-12
nitric oxide synthase inhibitors, value in osteoarthritis 51
nitric oxide synthases, role in ulcer healing 57
non-steroidal anti-inflammatory drugs (NSAIDs) 54-5
classification 61
gastric side effects 56-9
mechanism of action 55-6
safety monitoring 79
use in carpal tunnel syndrome 24
use in elderly people 105-6
use in gout 190, 192
use in osteoarthritis 50-1
use in patients with cardiovascular risk 63
use during pregnancy 95
use in pseudogout 197
use in SLE 126
nuclear factor-κ-beta (NF-κB) pathway 53, 240
nucleolar staining, ANA 110
Nurses Health Initiative 218
Nurses’ Health Study, smoking, relationship to RA risk 74
nutritional supplements, value in osteoarthritis 46-7, 52

obesity
association with osteoarthritis 41-2, 43, 45
association with plantar fasciitis 34
and joint replacement surgery 65-6
as risk factor for osteoarthritis 104
occupational risk factors
osteoarthritis 43
rheumatoid arthritis 74
oedematous stage, scleroderma 141
oesophageal dysfunction, scleroderma 141, 143-4
oestrogen
effect on osteoarthritis risk 43
oestrogen – contd
  effect on rheumatoid arthritis risk 74, 75
oestrogen therapy
  in osteoarthritis 51
  in osteoporosis 218, 231
  see also hormone replacement therapy (HRT)
oligoarthritis 3
olive oil 98
omega-3 friendly foods 101
omega-3 oil 98
  benefits in rheumatoid arthritis 82–3, 99
O’nyong-nyong 208
opioids, use in chronic low back pain 177
oral contraceptive pills, use in SLE 119
orlistat 45
orthoses
  value in osteoarthritis 47
  value in plantar fasciitis 35
osteitis fibrosa cystica (high turnover bone disease) 247
osteoarthritis 39–40, 103–4
  aetiology 41
  association with diabetes 211
  comparison with pseudogout 196
  drug treatment 50–3
  non-pharmacological treatment 45–9
  radiological severity scoring 40
  risk factors 41–3
  secondary causes 40
osteoblast apoptosis inhibition 240
osteoblasts, effect of corticosteroids 238
osteoclast differentiation 243
osteoclasts, activation at menopause 218
osteoid 247
osteomalacia 247
osteomyelitis 201, 203
  plasma procalcitonin 10
  spinal 172, 204
osteonecrosis, as side effect of bisphosphonates 224
osteopenia, indications for bisphosphonates 223
osteoporosis 218, 231, 234
  drug treatments 218, 231, 234
  bisphosphonates 219–20, 223–4
  combination treatment 229–30
  raloxifene 227–8
  sequential treatments 230
  strontium ranelate 228–9, 230
  teriparatide 229, 230
  third generation SERMS 230
  glucocorticoid-induced 238–9
  investigations 226
  male 133–5
  diagnosis and management 236
  management 225, 226
prevention in long-term steroid therapy 162
  risk factors 218–19
  risk in insulin-requiring diabetes 213–14
  risk from thiazolidinediones 250
  risk management 220
  spinal fracture 172
osteoprotegerin (OPG) 218, 238, 243, 248
osteosarcoma, as side effect of teriparatide 229
outcome measures, RA and AS 88–92
oxicams 61
p-ANCA 156–7
Paget’s disease 241–2
  avoidance of teriparatide 229
  comorbidities 245
  complications 242
  genetic factors 243
  investigation and management 242–3, 244
  pain 2
  pain management
    in fibomyalgia syndrome 30
    in low back pain 176
painful arc 13
painful joints
  acute monoarthritis, differential diagnosis 6–8
  new onset
    examination 3
    history-taking 2–3
    investigations 3–4
pamidronate 224
  structure and function 223
  use during corticosteroid therapy 238
  use in male osteoporosis 234
  use in neuropathic arthropathy 213
paracetamol 61
  value in osteoarthritis 50–1
parainfluenza virus 160
paramyotonia 255
parathyroid hormone (PTH) 247
  in evaluation of renal osteodystrophy 248
  recombinant see teriparatide
parathyroidectomy, in renal osteodystrophy 249, 250
parecoxib, cardiovascular side effects 62
partial androgen deficiency in aging men (PADAM) 234–5
parvovirus B19 160, 206–7, 208–9
patient education, rheumatoid arthritis 84
peak bone mineral density 218
peginterferon-α therapy, hepatitis C 207
pentazocine 51
peptidylarginine deaminases (PADIs) 72
periodontal disease, effect on rheumatoid arthritis 75
Phalen’s sign 23
pharmacogenomics 150
Phos-Ex (calcium acetate) 250
phosphatase, use in chronic kidney disease 250
phosphoribosylpyrophosphate synthetase gene
mutations 186
photosensitivity, SLE 122, 126
pioglitazone, osteoporosis risk 214, 250
piroxicam, side effects 57
plantar fascia stretching 36
plantar fasciitis 33–5
management 35–7
plasmapheresis, use in vasculitides 157
pleural disease, SLE 123
Pogosta Disease 208
polyarteritis nodosa 155
polyarthritis 3
in elderly people 103
gout 106
osteoarthritis 103–4
rheumatoid arthritis 104–6
polymerase chain reaction (PCR) screening, in
diagnosis of infection 203
polymyalgia rheumatica (PMR) 105, 155,
159–60, 163–4
DHEA levels 162–3
epidemiology 162
investigation 161, 163
treatment 161–2, 163
polymyositis (PM) 260, 261
antinuclear antibodies 111, 112, 113
pathogenesis 264
polyphenols 100
value in osteoarthritis 52
Pompe disease 256
positron emission tomography (PET)
in diagnosis of giant cell arteritis 161
in diagnosis of infections 204
posterior compartment syndrome 24
prayer sign 212
prazosin, value in Raynaud’s phenomenon 137
prednisolone
in GCA and PMR 161
in inflammatory myopathies 262
intra-articular injection 51
risk of fracture 238
see also corticosteroid therapy
pregabalin, use in fibromyalgia syndrome 30
pregnancy
effect on rheumatoid arthritis risk 74
effect on rheumatoid diseases 93, 94
parvovirus B19 infection 208
use of azathioprine 127
use of hydroxychloroquine 126
preventive screening, SLE 124, 125–6
primary biliary cirrhosis, antinuclear antibodies 111
primary Raynaud’s phenomenon 135
PRIMO (Prediction of Muscle Risk in
Observational conditions) survey 267
probenecid 193
procainamide, association with DIL 118
procalcitonin (PCT) 10
as marker for infection 203
prolactin 93
prolapsed intervertebral discs 171, 172
discectomy 176
prostacyclin
effect of NSAIDs 61–2
value in Raynaud’s phenomenon 137
value in scleroderma 143
prostaglandin generation, COX-1 and COX-2 55
prostate cancer, androgen deprivation therapy 235
prostheses survival, joint replacement 66, 67–8
protein restriction, chronic kidney disease 187–8
proteinuria
in rheumatoid arthritis 78–9
in scleroderma 142
proton pump inhibitors, use with NSAIDs 56,
57, 59
pseudo gout 8, 9, 195–6
associated conditions 196–7
diagnosis 196
hereditary 197
role of ANKH mutations 198
toll-like receptors 198
treatment 197–8
Pseudomonas aeruginosa joint infections 201
psoriasis 3, 179
cardiovascular disease risk 182
in retrovirus infection 208
psoriatic arthritis 4, 179–80, 182–3
comparison with rheumatoid arthritis 180
diagnosis 180, 181
management 181–2
X-ray changes 78
PSORS loci 179
psychological disorders
in Behçet’s syndrome 166
in fibromyalgia syndrome 28
in Sjögren’s syndrome 132
psychological interventions, value in low back
pain 177
psychosis, in SLE 127
PTN22 gene 72
pulmonary artery hypertension (PAH)
bosentan therapy 144
scleroderma 142, 143
pulmonary embolism, risk after joint replacement surgery 67
pulmonary fibrosis, scleroderma 141-2, 143
pulmonary manifestations
dermatomyositis 261
Sjögren’s syndrome 131
pulseless disease (Takayasu’s arteritis) 155
purine metabolism 184-5
purine nucleoside phosphorylase deficiency 186
purine-rich foods 187
purpura 154, 158
pyrazolidine derivatives 61

quality of life, in psoriatic arthritis 182
quality of life evaluation 90-1
quercetin 100

radial neuritis 23
radiography
in gout 190
in low back pain 176
in osteomyelitis 203
in Paget’s disease 242
in pseudogout 196
in rheumatoid arthritis 78
vascular calcification 249
radionuclide scanning, in osteomyelitis 203
raloxifene 227-8, 231
in combination treatment 230
fracture prevention 224
RANK-RANKL pathway 218, 238, 240, 243
rapamycin, use in inflammatory myopathies 264
RAPTOR gene 179
rashes
butterfly 122
in dermatomyositis 261
rat-bite fever 201
Raynaud’s phenomenon 134-5
autoantibodies 111, 113
benefits of statins 144
pathogenesis 136
in scleroderma 141
treatment 136-8
reactive arthritis 4, 7
recurrent haemorrhagic shoulder of the elderly 14
red meat intake, relationship to RA risk 98
referred pain 3
around shoulder 11, 12
remitting seronegative symmetric synovitis with pitting oedema (RS3PE) 105
renal disease
in scleroderma 142, 143

Sjögren’s syndrome 131
in SLE 122, 124, 127, 150
renal osteodystrophy (ROD) 246-7, 251
adynamic bone disease 248
diagnosis and management 248
in early stage disease 250
high turnover bone disease (osteitis fibrosa cystica) 247
mixed 247
osteomalacia 247
renal side effects, NSAIDs 57
rofecoxib 63
resolvins 98
retinal vasculitis, Behçet’s syndrome 166
retroviruses 208
reverse Phalen’s sign 23
rhabdomyolysis, statin therapy 266, 267
rheumatoid arthritis 71-2
anti-CCP antibodies 79-80
antinuclear antibodies 111, 113
comparison with psoriatic arthritis 180
diagnosis 4-5, 77
investigations 78-9
diet, susceptibility factors 97-8
dietary supplements 99-100
disease-modifying antirheumatic drugs 83-4, 86
effect on fetus 94-5
effect of pregnancy 93
effect on pregnancy 96
effect of smoking 5, 85-6
in elderly people 104-6, 150
environmental factors 73-5
fertility 93-4
 genetic factors 72, 75
omega-3 oil supplementation 82-3
parvovirus B19 seropositivity 208-9
patient education 84
primary care and specialist liaison 79
prognostic markers 80
safety monitoring of medications 79
treatment algorithm 85
treatment response 84-5
treatment response evaluation 87-8, 90-2
rheumatoid factor (RF) 4, 72, 73, 77, 78, 156
in hepatitis C 207
in parvovirus B19 infection 207
in psoriatic arthritis 182
in rubella 207
ribavirin therapy, hepatitis C 207
rimonabant 45
risedronate 223
fracture prevention 224
long-term use 224
use during corticosteroid therapy 238
use in male osteoporosis 234
use in osteoarthritis 104
use in Paget's disease 243
rituximab 149
use in inflammatory myopathies 264
use in SLE 128
use in vasculitides 157
RNA-induced silencing complex (RISC) 209
rofecoxib
  cardiovascular risk 61, 62, 63
  renal toxicity 63
rosiglitazone, osteoporosis risk 214, 250
Ross River Virus 208
rosuvastatin 269
dosage in Asian patients 267
rotator cuff disease 11, 13-14, 212
  clinical assessment 11-13
  imaging 16
rubella 206, 207
RUTH (Raloxifene Use for The Heart) study 228

sacroiliitis 4
salicylates 61
  see also aspirin, low dose
Sandimmune (cyclosporin) 149
SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis) syndrome 180
sarcoidosis 132
Schirmer's test 130
sciatica, value of epidural steroid injection 176-7
scleroderma 140-2, 146
  antinuclear antibodies 111, 112
  pathophysiology 142-3
  prognosis 142
  similarity to graft-versus-host disease 144
  treatment 143-4
sclerosant injections, low back pain 176
sildenafil, value in Raynaud's phenomenon 137-8
selective oestrogen receptor modulators (SERMs) 227
  third generation 230
  see also raloxifene
selective serotonin reuptake inhibitors
  use in fibromyalgia syndrome 30
  use in Raynaud's phenomenon 137
SELENA (Safety of Estrogens in Lupus Erythematosus National Assessment) trials 119
sequestosome 1
signal recognition particle (SRP) antibodies 262
side effects
  of allopurinol 192
  of androgen therapy 235
  of azathioprine 148
  of bisphosphonates 224
  of colchicine 190
  of corticosteroids 106, 127, 148
  of cyclophosphamide 148
  of cyclosporin 149
  of hydroxychloroquine 149
  of leflunomide 148
  of methotrexate 148
  of mycophenolate mofetil 148
  of NSAIDs 57
    cardiac 61-4
    gastrointestinal 55, 56-9
  of raloxifene 228
  of statins 211-12, 266-70
  of strontium ranelate 228
  of sulphasalazine 149
  of teriparatide 229
sicca syndrome 130
sildenafil, value in Raynaud's phenomenon 137-8
simvastatin, combination with ezetimibe 269
Sindbis Virus 208
sirolimus (Rapamune) 148
Sjögren's syndrome 129-30
  anti-centromere antibodies 132
  antiviral antibodies 206
  association with hepatitis C 207
  autoantibodies 111, 113
  dry eyes 130
  dry mouth 130-1
  extraglandular manifestations 131-2
  fertility 96
Sjögren’s syndrome – contd
  infections as trigger 132
  international consensus criteria for diagnosis 130
  investigation and management algorithm 133
  skin lesions, Sjögren’s syndrome 131
  ‘slapped cheek’ disease (erythema infectiosum) 206
SLC9A3R1 gene 179
SLC11A1 gene 167
SLC22A4 gene 72
SLC22A12 (URAT1) 185
sleep abnormalities, in fibromyalgia syndrome 28, 29
small vessel vasculitis 154–5
smoking 112–13
  effect on ankylosing spondylitis 91
  effect on osteoarthritis 42
  effect on Raynaud’s phenomenon 136
  effect on rheumatoid arthritis 5, 74, 75, 85–6
  effect on SLE 126
SOTI (Spinal Osteoporosis Therapeutic Intervention) trial 228
SPARC 140
speckled staining, ANA 110, 117
spinal canal stenosis 171
  surgery 176
spinal cord stimulation, Raynaud’s phenomenon 137
spinal fracture 172
spinal function assessment 88–90
spinal fusion surgery 176
spinal infections 172, 203, 204
spondyloarthritis, effect of pregnancy 94
spondylodiscitis 180
spondylolisthesis 171
statins
  benefits in scleroderma 144–5
  cholesterol-lowering activity 266
  muscle symptoms 212, 266–7, 269–70
  diagnosis and management 267–9
  pathogenesis 269
  rhabdomyolysis 267
steroid myopathy 257, 258, 259
steroids see corticosteroid therapy
Streptococcus mitis 201
stress reduction, fibromyalgia syndrome 31
stress risk, raloxifene 228
strontium ranelate 228–9, 230, 231
  fracture prevention 224
subacute cutaneous lupus 118
sulphasalazine 149
  effect on fertility 94
  safety monitoring 79
  use during pregnancy 95
  use in psoriatic arthritis 181
sulphate intake, relationship to osteoarthritis risk 49
sulphinpyrazone 191, 193
superficial osteomyelitis 201
superoxide dismutase gene, Val16 allele 167
suprascapular neuritis 22
swollen joint count (SJC) 88
synovial fluid characteristics 8–9
systemic lupus erythematosus (SLE) 3, 4, 78, 121, 128
  ACR classification criteria 117
  aetiology 117–18, 119–20
  antiviral antibodies 206
  autoantibodies 110, 111, 113
  cardiovascular disease risk 125–6
  central nervous system involvement 127
  clinical features 122–3
  diagnosis 116–17
  drug-induced 118
  effect on fetus 94–5
  effect of pregnancy 93
  effect on pregnancy 94, 96
  fertility 94
  monitoring 123–5
  nephritis 127
  preventive screening 124, 125–6
  risk from smoking 74
  SELENA trials 119
  treatment 126–7
systemic sclerosis 140
  autoantibodies 111, 112, 113
  effect of pregnancy 94
  T score, definition of osteoporosis 217–18
tacrolimus 149
  use in psoriatic arthritis 181
Takayasu’s arteritis (pulseless disease) 155
tamoxifen 228
taping
  value in osteoarthritis 47
  value in plantar fasciitis 35
Tarui disease 257
temporal artery biopsy 155, 161, 162, 164
tender joint count (TJC) 88
tendinopathy, neural aetiology 16
tennis elbow 18–19
  RCT of treatments 20
teriparatide 224, 226, 229, 231
  in combination treatment 230
  cost-benefit analysis 230
  use during corticosteroid therapy 239
  use in male osteoporosis 234
testosterone, use in male osteoporosis 234–5
Index

tetracycline labelling, bone biopsy 248
tetracyclines, value in osteoarthritis 51, 53, 104
Th1 and Th2 cell patterns 93
thalidomide, use in Behçet’s syndrome 166
therapeutic monitoring, immunosuppressives 149–50, 151
thermal biofeedback (TBF) 136–7
thiazolidinediones, osteoporosis risk 214, 250
thiopurine methyltransferase levels 150
Thomsen’s disease 255
thoracic outlet syndromes 22
three-joint complex, spine 171
thrombosis, risk during pregnancy 94
thromboxane A₂, effect of NSAIDs 61–2
thyroiditis, in Sjögren’s syndrome 132
tiludronate
structure and function 222–3
use in Paget’s disease 243
Tinel’s sign 23
tissue-engineering, osteoarthritis 52
Titralac 250
tizanidine, use in fibromyalgia syndrome 30
TNFR2 gene 72
TNFRSF11B mutations 243
toll-like receptors (TLRs) 198
tongue, claudication 155
tophi 189
dissolution 193
topical NSAIDs, value in osteoarthritis 51
topoisoerase 1 140
tragus to wall measurement 89, 90
tramadol 30
use in osteoarthritis 51
transforming growth factor-β (TGF-β), role in scleroderma 143
transplant patients, cyclosporin therapy 149
treatment response evaluation, AS and RA 87–92
triamcinolone
epidural injection 177
intra-articular injection 51
tricyclic antidepressants, use in fibromyalgia syndrome 30
trigger point injections
fibromyalgia syndrome 31
low back pain 176
trigger points, fibromyalgia syndrome 28, 29
triphasic colour changes, Raynaud’s 135
TROPOS (Treatment of Peripheral Osteoporosis Study) 228
tumour necrosis factor (TNF)-α-1031C allele 166
tumour necrosis factor (TNF)-α antagonists 51, 80, 83, 85, 149, 150
safety monitoring 79
tumour necrosis factor (TNF)-α-1031C allele, association with RA 72
turmeric, effect on inflammation 100
twin studies
osteoarthritis 41
rheumatoid arthritis 72
U3-RNP antibodies, scleroderma 142
ulcer healing, role of COX isoenzymes 57
ulcers
in Behçet’s syndrome 166
in scleroderma 141
ulnar neuritis 22–3
ultrasound
in carpal tunnel syndrome 24–5
in giant cell arteritis 161
unicompartmental knee arthroplasty 68
URAT1 (SLC22A12) 185
urate levels, in diagnosis of gout 7
uric acid metabolism 184–5
see also gout; hyperuricaemia
uricase 184
uricase preparations, use in gout prophylaxis 192
uricosuric agents 190, 191, 193
urinary C-terminal peptide of collagen type II 43
uveitis, Behçet’s syndrome 166
vascular calcification, in renal disease 249–50, 251
vascular dysfunction
in hyperparathyroidism 250
in scleroderma 143
vascular endothelial growth factor (VEGF) polymorphisms, psoriasis 182
vascular theory, rotator cuff disease 14
vasculitides 153–4
ANCA 157–8
antibody therapies 158
classification 154
diagnosis 155–7
effect of pregnancy 94
large vessel 155
medium vessel 155
small vessel 154
treatment 157, 158
see also Behçet’s syndrome; giant cell arteritis (GCA)
VDR gene 41
vegetarian/vegan diets 99
vertebral fracture prevention 224
vertebral fracture prevention – contd
  raloxifene 227
  strontium ranelate 228
  teriparatide 229
VIGOR (Vioxx Gastrointestinal Outcomes Research) 57, 61
viral arthritis 205–6
  alphaviruses 208
  causes 206
  diagnosis and treatment 209–10
  hepatitis C 207–8, 209
  parvovirus B19 206–7, 208–9
  retroviruses 208
  rubella 207
viscosupplementation 47, 49
visual symptoms, GCA 161
vitamin C intake, relationship to RA risk 97, 98
vitamin C status, relationship to risk of
  osteoarthritis 46
vitamin D 219
  calcitriol (1, 25-dihydroxy-vitamin D₃) 247
  vitamin D deficiency 221
vitamin D receptor gene 41
vitamin D status
  in male osteoporosis 235
  relationship to rheumatoid arthritis risk 74
  relationship to risk of type 2 diabetes 250–1
vitamin D treatment 218, 231
  in chronic kidney disease 250
in corticosteroid therapy 238
  men 234
  Vytorin 269
walking sticks, use in osteoarthritis 47
warfarin, interaction with allopurinol 192
Wegener’s granulomatosis 154–5
  ANCA 157
weight reduction
  value before joint replacement surgery 65–6
  value in fibromyalgia syndrome 31
  women, rheumatoid arthritis risk 74
  wrist splints, carpal tunnel syndrome 24
X-rays see radiography
xanthine oxidase (XO) 184
xanthine oxidase inhibitors 188
  see also allopurinol
xerostomia
  differential diagnosis 131
  Sjögren’s syndrome 130–1
zoledronate
  dosage 224
  structure and function 223
  use in Paget’s disease 243, 245